Bone markers in the management of patients with skeletal metastases

Laurence M. Demers

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND. Biochemical markers of bone remodeling have been used as surrogate markers to manage patients with metastatic bone disease. Markers of the bone resorptive process, such as the bone collagen breakdown products N-telopeptide and C-telopeptide, are useful markers for monitoring the response and efficacy of antiresorptive therapy and to assess disease progression in patients with osteolytic bone disease. Recently discovered markers of osteoclastogenesis, osteoprotegerin (OPG) and the soluble form of the receptor activator for nuclear factor (NF)-κB (RANK-L), also are candidate markers of the bone metastases process and offer potential as surrogate markers of tumor-induced osteoclastogenesis. METHODS. Immunoassays have been developed that can determine blood and urine levels of the telopeptides associated with bone collagen breakdown. In addition, immunoassays now are available that can measure both OPG and the soluble form of RANK-L in blood and tissues as markers of osteoclastogenesis. RESULTS. The measurement of bone collagen breakdown products and specific factors associated with the process of osteoclastogenesis have been applied to the management and assessment of patients with metastatic bone disease. Results indicate that these surrogate markers can be useful in determining response to antiresorptive therapy, in selecting optimal dosage, and as markers of disease progression. CONCLUSIONS. Although they show promise, questions remain whether blood measurements of surrogate markers of osteoclastogenesis, like OPG and RANK-L, will be useful in both assessing and managing patients with metastatic bone disease.

Original languageEnglish (US)
Pages (from-to)874-879
Number of pages6
JournalCancer
Volume97
Issue number3 SUPPL.
StatePublished - Feb 1 2003

Fingerprint

Osteogenesis
Bone Diseases
Osteoprotegerin
Biomarkers
Neoplasm Metastasis
Bone and Bones
Collagen
Immunoassay
Disease Progression
L Forms
Bone Remodeling
Cytoplasmic and Nuclear Receptors
Urine
Therapeutics
Neoplasms
collagen type I trimeric cross-linked peptide

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Demers, L. M. (2003). Bone markers in the management of patients with skeletal metastases. Cancer, 97(3 SUPPL.), 874-879.
Demers, Laurence M. / Bone markers in the management of patients with skeletal metastases. In: Cancer. 2003 ; Vol. 97, No. 3 SUPPL. pp. 874-879.
@article{84a1d3f70edb45a0bd3b8ee87f31c9a3,
title = "Bone markers in the management of patients with skeletal metastases",
abstract = "BACKGROUND. Biochemical markers of bone remodeling have been used as surrogate markers to manage patients with metastatic bone disease. Markers of the bone resorptive process, such as the bone collagen breakdown products N-telopeptide and C-telopeptide, are useful markers for monitoring the response and efficacy of antiresorptive therapy and to assess disease progression in patients with osteolytic bone disease. Recently discovered markers of osteoclastogenesis, osteoprotegerin (OPG) and the soluble form of the receptor activator for nuclear factor (NF)-κB (RANK-L), also are candidate markers of the bone metastases process and offer potential as surrogate markers of tumor-induced osteoclastogenesis. METHODS. Immunoassays have been developed that can determine blood and urine levels of the telopeptides associated with bone collagen breakdown. In addition, immunoassays now are available that can measure both OPG and the soluble form of RANK-L in blood and tissues as markers of osteoclastogenesis. RESULTS. The measurement of bone collagen breakdown products and specific factors associated with the process of osteoclastogenesis have been applied to the management and assessment of patients with metastatic bone disease. Results indicate that these surrogate markers can be useful in determining response to antiresorptive therapy, in selecting optimal dosage, and as markers of disease progression. CONCLUSIONS. Although they show promise, questions remain whether blood measurements of surrogate markers of osteoclastogenesis, like OPG and RANK-L, will be useful in both assessing and managing patients with metastatic bone disease.",
author = "Demers, {Laurence M.}",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "97",
pages = "874--879",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 SUPPL.",

}

Demers, LM 2003, 'Bone markers in the management of patients with skeletal metastases', Cancer, vol. 97, no. 3 SUPPL., pp. 874-879.

Bone markers in the management of patients with skeletal metastases. / Demers, Laurence M.

In: Cancer, Vol. 97, No. 3 SUPPL., 01.02.2003, p. 874-879.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone markers in the management of patients with skeletal metastases

AU - Demers, Laurence M.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - BACKGROUND. Biochemical markers of bone remodeling have been used as surrogate markers to manage patients with metastatic bone disease. Markers of the bone resorptive process, such as the bone collagen breakdown products N-telopeptide and C-telopeptide, are useful markers for monitoring the response and efficacy of antiresorptive therapy and to assess disease progression in patients with osteolytic bone disease. Recently discovered markers of osteoclastogenesis, osteoprotegerin (OPG) and the soluble form of the receptor activator for nuclear factor (NF)-κB (RANK-L), also are candidate markers of the bone metastases process and offer potential as surrogate markers of tumor-induced osteoclastogenesis. METHODS. Immunoassays have been developed that can determine blood and urine levels of the telopeptides associated with bone collagen breakdown. In addition, immunoassays now are available that can measure both OPG and the soluble form of RANK-L in blood and tissues as markers of osteoclastogenesis. RESULTS. The measurement of bone collagen breakdown products and specific factors associated with the process of osteoclastogenesis have been applied to the management and assessment of patients with metastatic bone disease. Results indicate that these surrogate markers can be useful in determining response to antiresorptive therapy, in selecting optimal dosage, and as markers of disease progression. CONCLUSIONS. Although they show promise, questions remain whether blood measurements of surrogate markers of osteoclastogenesis, like OPG and RANK-L, will be useful in both assessing and managing patients with metastatic bone disease.

AB - BACKGROUND. Biochemical markers of bone remodeling have been used as surrogate markers to manage patients with metastatic bone disease. Markers of the bone resorptive process, such as the bone collagen breakdown products N-telopeptide and C-telopeptide, are useful markers for monitoring the response and efficacy of antiresorptive therapy and to assess disease progression in patients with osteolytic bone disease. Recently discovered markers of osteoclastogenesis, osteoprotegerin (OPG) and the soluble form of the receptor activator for nuclear factor (NF)-κB (RANK-L), also are candidate markers of the bone metastases process and offer potential as surrogate markers of tumor-induced osteoclastogenesis. METHODS. Immunoassays have been developed that can determine blood and urine levels of the telopeptides associated with bone collagen breakdown. In addition, immunoassays now are available that can measure both OPG and the soluble form of RANK-L in blood and tissues as markers of osteoclastogenesis. RESULTS. The measurement of bone collagen breakdown products and specific factors associated with the process of osteoclastogenesis have been applied to the management and assessment of patients with metastatic bone disease. Results indicate that these surrogate markers can be useful in determining response to antiresorptive therapy, in selecting optimal dosage, and as markers of disease progression. CONCLUSIONS. Although they show promise, questions remain whether blood measurements of surrogate markers of osteoclastogenesis, like OPG and RANK-L, will be useful in both assessing and managing patients with metastatic bone disease.

UR - http://www.scopus.com/inward/record.url?scp=0037303695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037303695&partnerID=8YFLogxK

M3 - Article

C2 - 12548589

AN - SCOPUS:0037303695

VL - 97

SP - 874

EP - 879

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 SUPPL.

ER -